Bremelanotide

Bremelanotide is a melanocortin receptor agonist peptide used to treat hypoactive sexual desire disorder in premenopausal women.

Brief glance

The primary outcome is Sexual Health. This compound is considered a Peptide. It may be compounded in 503A pharmacies where allowed. It is not listed under a DEA schedule.

Overview

Bremelanotide, sold as Vyleesi, is a melanocortin receptor agonist indicated for treating acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It is administered as a 1.75 mg/0.3 mL subcutaneous injection via a single-dose autoinjector, typically 45 minutes before anticipated sexual activity, with a limit of one dose per 24 hours and no more than 8 doses per month. Common side effects include nausea, headache, and transient increases in blood pressure.

Bremelanotide is a synthetic heptapeptide and melanocortin receptor agonist developed to treat hypoactive sexual desire disorder in premenopausal women. The medication, marketed under the brand name Vyleesi, was approved by the FDA in 2019 as a first-in-class treatment and is administered via subcutaneous injection through a prefilled autoinjector. Bremelanotide functions by activating melanocortin receptors in the central nervous system, though the precise mechanism by which this activation improves sexual desire remains unclear. Common side effects include nausea, injection site pain, and headache, with some patients experiencing temporary increases in blood pressure and darkening of the gums, face, and breasts. The drug is a cyclic analogue of alpha-melanocyte-stimulating hormone and represents an important pharmacological advancement for women experiencing clinically significant sexual desire difficulties.

Benefits

Bremelanotide is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women, demonstrating statistically significant increases in sexual desire and reductions in associated distress compared to placebo in two phase 3 trials.¹,²,³,⁴,⁵ It improves coprimary endpoints including the number of satisfying sexual events and scores on the Female Sexual Function Index, with clinically meaningful benefits across patient subgroups.¹,⁶ Administered subcutaneously as needed, it activates melanocortin-4 receptors to enhance central arousal pathways, independent of hormonal influences.¹,⁵,⁶

Side effects

The most common side effects of bremelanotide are nausea (affecting up to 40% of users, especially after the first dose and typically lasting about 2 hours), flushing (20%), injection site reactions such as pain, redness, itching, or bruising (13%), and headache (11%)⁷,⁸,⁹. Less frequent effects include vomiting, tiredness, dizziness, cough, nasal stuffiness, and tingling sensations⁷,⁸,¹⁰. Serious safety considerations involve transient increases in blood pressure and decreases in heart rate lasting up to 12 hours post-dose, which may pose risks for patients with cardiovascular disease, as well as potential focal hyperpigmentation (especially of the face, gums, or breasts that may not reverse), allergic reactions, and rare cases of hepatotoxicity⁷,⁸,⁹,¹¹. Nausea often improves with subsequent doses, and antiemetics may be prescribed prophylactically⁴,⁷,⁸. Patients should monitor for these effects and report severe or persistent symptoms to their healthcare provider, avoiding use more frequently than recommended to minimize risks⁷,⁸,¹¹. Overdose may exacerbate nausea, hyperpigmentation, and blood pressure elevations, managed supportively⁵.

Mechanisms of action

Bremelanotide acts as a non-selective agonist of melanocortin receptors, with potency in the order MC1R > MC4R > MC3R > MC5R > MC2R, primarily engaging MC4R in the central nervous system.⁵,⁹ These G protein-coupled receptors, upon activation, stimulate adenylate cyclase to increase cyclic AMP levels, triggering downstream neural signaling in areas like the hypothalamus.⁵,¹² In the medial preoptic area (mPOA), presynaptic MC4R activation on neurons promotes dopamine release, an excitatory neurotransmitter that enhances sexual desire and arousal pathways.¹²,¹³ The precise translation of this melanocortin agonism to improved hypoactive sexual desire disorder remains incompletely understood, though modulation of dopamine and possibly serotonin contributes.⁵,¹²,¹⁴